Pregabalin News and Research

RSS
Pfizer’s Lyrica does not affect reproductive function in healthy males

Pfizer’s Lyrica does not affect reproductive function in healthy males

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Top-line results in Pfizer's Lyrica long term safety study for Generalized Anxiety Disorder

Delaware district court upholds Pfizer's patents for LYRICA to treat pain and seizures

Delaware district court upholds Pfizer's patents for LYRICA to treat pain and seizures

Pfizer receives FDA approval for Lyrica to manage neuropathic pain associated with SCI

Pfizer receives FDA approval for Lyrica to manage neuropathic pain associated with SCI

Pfizer announces results from Lyrica clinical studies on fibromyalgia

Pfizer announces results from Lyrica clinical studies on fibromyalgia

Pfizer terminates Lyrica Phase 3 trial on neuropathic pain associated with HIV neuropathy

Pfizer terminates Lyrica Phase 3 trial on neuropathic pain associated with HIV neuropathy

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

Pfizer’s Lyrica Phase 3 study on pDPN fails to meet primary endpoint

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Pfizer Lyrica Phase 3 study on Central Neuropathic Pain meets primary endpoint

Ideal psychotropic drug may cause physical dependence

Ideal psychotropic drug may cause physical dependence

New guideline on most effective treatments for diabetic nerve pain

New guideline on most effective treatments for diabetic nerve pain

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Catalyst’s CPP-115 improves retinal safety profile than vigabatrin

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

Pfizer announces approval of Lyrica capsules for peripheral neuropathic pain

New epilepsy drugs give more options, but make treatment decisions more complex: Epilepsy specialist

New epilepsy drugs give more options, but make treatment decisions more complex: Epilepsy specialist

FDA grants orphan-drug designation to Catalyst's CPP-115 investigational drug

FDA grants orphan-drug designation to Catalyst's CPP-115 investigational drug

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

Vimpat provides long-term additional partial-onset seizure control when added to broad range of AEDs

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Forest Laboratories, Gedeon Richter report positive results from radiprodil Phase II study for DPNP pain

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery

Study demonstrates effectiveness of pre-emptive pain management protocol using pregabalin in urologic surgery

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Catalyst Pharmaceutical Partners to present overview of CPP-115 compound at epilepsy conference

Peripheral nerve stimulation promising for treatment of post-herpetic neuralgia

Peripheral nerve stimulation promising for treatment of post-herpetic neuralgia

FDA issues Pfizer a Complete Response letter for Lyrica GAD monotherapy treatment

FDA issues Pfizer a Complete Response letter for Lyrica GAD monotherapy treatment